Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Otividex in Meniere's Disease
NCT02612337Phase 3Completed
- Sponsor
- Otonomy, Inc.
- Start
- Oct 2015
- Primary completion
- Jul 2017
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Otividex in Meniere's disease (MD), sponsored by Otonomy, Inc.. Started Oct 2015; status: completed.
02
Drugs
Otividex
03
Conditions
Meniere's disease (MD)
Beyond the preview
Go deeper on NCT02612337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02612337.